(Q53425366)

14 May 2018

title

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. (English)

1 reference

14 May 2018

author name string

Irfan Kayani

1

1 reference

14 May 2018

Jamshed B Bomanji

2

1 reference

14 May 2018

Ashley Groves

3

1 reference

14 May 2018

Gerard Conway

4

1 reference

14 May 2018

Sveto Gacinovic

5

1 reference

14 May 2018

Thida Win

6

1 reference

14 May 2018

John Dickson

7

1 reference

14 May 2018

Martyn Caplin

8

1 reference

14 May 2018

Peter Joseph Ell

9

1 reference

14 May 2018

language of work or name

English

0 references

publication date

1 June 2008

1 reference

14 May 2018

published in

Cancer

1 reference

14 May 2018

volume

112

1 reference

14 May 2018

issue

11

1 reference

14 May 2018

page(s)

2447-2455

1 reference

14 May 2018

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Radiolabelling DOTA-peptides with 68Ga

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Functional imaging of malignant paragangliomas and carcinoid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Peptide receptors as molecular targets for cancer diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

The diagnosis and medical management of advanced neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23469

7 January 2021

https://api.fatcat.wiki/v0/release/gm5wse5bfrcdpan2zfeeo7ih5a

Identifiers

1 reference

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_gm5wse5bfrcdpan2zfeeo7ih5a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gm5wse5bfrcdpan2zfeeo7ih5a

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/gm5wse5bfrcdpan2zfeeo7ih5a

30 July 2022